Pioneer Trust Bank N A OR Has $7.91 Million Holdings in Abbott Laboratories $ABT

Pioneer Trust Bank N A OR increased its stake in Abbott Laboratories (NYSE:ABT) by 0.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 58,155 shares of the healthcare product maker’s stock after purchasing an additional 485 shares during the quarter. Abbott Laboratories makes up 2.0% of Pioneer Trust Bank N A OR’s investment portfolio, making the stock its 17th largest holding. Pioneer Trust Bank N A OR’s holdings in Abbott Laboratories were worth $7,910,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABT. Advyzon Investment Management LLC grew its stake in Abbott Laboratories by 33.4% in the 2nd quarter. Advyzon Investment Management LLC now owns 4,732 shares of the healthcare product maker’s stock valued at $644,000 after buying an additional 1,185 shares during the last quarter. VeraBank N.A. lifted its position in shares of Abbott Laboratories by 4.2% during the 2nd quarter. VeraBank N.A. now owns 20,244 shares of the healthcare product maker’s stock worth $2,753,000 after purchasing an additional 810 shares during the last quarter. Montag A & Associates Inc. grew its holdings in Abbott Laboratories by 3.8% in the 2nd quarter. Montag A & Associates Inc. now owns 108,834 shares of the healthcare product maker’s stock valued at $14,803,000 after buying an additional 3,993 shares during the last quarter. 49 Wealth Management LLC lifted its holdings in shares of Abbott Laboratories by 3.6% during the second quarter. 49 Wealth Management LLC now owns 3,818 shares of the healthcare product maker’s stock worth $519,000 after buying an additional 131 shares during the last quarter. Finally, Laffer Tengler Investments Inc. grew its stake in shares of Abbott Laboratories by 57.2% in the second quarter. Laffer Tengler Investments Inc. now owns 3,492 shares of the healthcare product maker’s stock worth $475,000 after acquiring an additional 1,270 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $125.88 on Tuesday. The stock has a market capitalization of $218.89 billion, a price-to-earnings ratio of 15.77, a price-to-earnings-growth ratio of 2.36 and a beta of 0.68. The business’s fifty day moving average price is $130.65 and its two-hundred day moving average price is $131.39. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting the consensus estimate of $1.30. The business had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.9%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ABT. Morgan Stanley increased their price target on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Weiss Ratings restated a “buy (b)” rating on shares of Abbott Laboratories in a research note on Wednesday, October 8th. Wells Fargo & Company raised their price objective on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Evercore ISI lowered their price objective on Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 15th. Finally, Raymond James Financial lifted their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.